BridgeMD
New treatment option for Heart Failure
Official title Improving Care and Mental Well-Being for Adults With Heart Failure
ClinicalTrials.gov ID: NCT07313657
What this study is testing
- What it's testing
- Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- For Patients (Surveys and Optional Interviews):
- Patients at risk of heart failure (e.g., irregular heartbeat, coronary artery disease, a past heart attack, high blood pressure that is being...
- Angiotensin receptor-neprilysin inhibitors (ARNI), called sacubitril-valsartan
- Angiotensin converting enzyme inhibitors (ACEi), called "prils"
- Angiotensin-receptor blockers (ARBs), called "sartans"
You likely can't join if
- Inability to provide informed consent (e.g., due to cognitive impairment or language barriers without translated support)
- Participants who do not have access to the internet will not be able to use the web-tool. For Healthcare Providers
- Providers that are not involved in the care of heart failure patients
See the full eligibility criteria
- For Patients (Surveys and Optional Interviews):
- Patients at risk of heart failure (e.g., irregular heartbeat, coronary artery disease, a past heart attack, high blood pressure that is being treated, cardiomyopathy), or with a self-reported/documented diagnosis of...
- Angiotensin receptor-neprilysin inhibitors (ARNI), called sacubitril-valsartan
- Angiotensin converting enzyme inhibitors (ACEi), called "prils"
- Angiotensin-receptor blockers (ARBs), called "sartans"
- Beta-blockers, called "lols"
- Mineralocorticoid receptor antagonists (MRAs)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors, called "flozins"
- Receiving care at one of the participating pilot test sites or if they found their way to the tool website
- Willing and able to provide informed consent and name, email address and phone number for follow-up contact (for survey and interview) Caregivers (Optional interviews):
- Caregivers who support adult(s) with heart failure.
- Inability to provide informed consent (e.g., due to cognitive impairment or language barriers without translated support)
- Participants who do not have access to the internet will not be able to use the web-tool. For Healthcare Providers
- Providers that are not involved in the care of heart failure patients
The study team makes the final eligibility decision.
Where it's taking place
- Cornwall, Ontario, Canada
- Limoges, Ontario, Canada
- Orléans, Ontario, Canada
- Ottawa, Ontario, Canada
- Winchester, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cornwall, Ontario, Canada; Limoges, Ontario, Canada; Orléans, Ontario, Canada; Ottawa, Ontario, Canada; Winchester, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.